AI Medical Compendium Topic

Explore the latest research on artificial intelligence and machine learning in medicine.

Darunavir

Showing 1 to 3 of 3 articles

Clear Filters

Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.

Antiviral therapy 35485333
BACKGROUND: Primary analysis at 24 weeks showed that switching to rilpivirine plus darunavir/cobicistat was non-inferior to continuing a standard three-drug antiretroviral regimen in virologically suppressed people with HIV. We present efficacy and s...
Adult Cobicistat Darunavir HIV Infections HIV-1 Humans Pharmaceutical Preparations Rilpivirine RNA United States Viral Load
View on PubMed DOI

Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes.

HIV research & clinical practice 35234092
Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to viral suppression in...
Anti-HIV Agents Darunavir HIV Infections HIV-1 Humans Ritonavir
View on PubMed

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

HIV clinical trials 30890064
BACKGROUND: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.
Adult Aged Cohort Studies Darunavir Female Heterocyclic Compounds, 3-Ring HIV Infections HIV Integrase Inhibitors HIV Protease Inhibitors HIV-1 Humans Italy Male Middle Aged Oxazines Piperazines Pyridones Reproducibility of Results Salvage Therapy
View on PubMed DOI
Popular Topics
Recent Journals